Treatment
Sorafenib
4
Conditions
53
Trials
16K
Participants
40%
Average Safety
Condition Evidence
Liver cancer due to alcohol use
8 trials · 4,500 participants
55% effectiveness · 55% safety
Liver cancer due to hepatitis B
15 trials · 2,500 participants
70% effectiveness · 30% safety
Liver cancer due to NASH
10 trials · 5,000 participants
70% effectiveness · 45% safety
Thyroid cancer
20 trials · 4,000 participants
60% effectiveness · 30% safety